Ex Vivo Culture of Patient Tissue & Examination of Gene Delivery
December 20th, 2010
This article describes the culture of patient tissue slices for gene delivery studies and subsequent analysis of gene expression using IVIS bioluminescence imaging.
Hello everyone. My name is Simon Regenron. I'm one of the surgical registrars here in the Core Cancer Research Center in Ireland.
The technique I'm showing you today involves the use of intact patient tissue for the study of gene delivery. Gene therapy offers exciting therapeutic approaches for the treatment of cancer. However, have recent clinical trials have failed to replicate results found in animal models.
The main reason, I believe, to be the variation in tissue physiology between animal and man tumor heterogeneity and differences in tumor phenotype. X vivo patient tissue model I'm demonstrating is the most stringent preclinical model available today. This model involves slicing patient tissue into thin slices and maintaining these slices in vitro.
Many gene delivery methods may be tested using this model, the viral vectors and DNA constructs I'm using express a firefly luciferase under the transcription control of the CMV promoter, allowing quantification of gene expression by bioluminescent Imaging. Okay, let's go start this. The materials that are needed for this model are fresh human tissue, vibram tissue slicing system, physical gene delivery methods to be Assessed.
An ultrasound machine, six plate tissue culture dish 27 gauge incident needle non-toxic glue gene delivery vector, which may be viral and non-viral media Containing serum and culture media. The block of tissue is attached to the slicing stage using derma bond ad heath. The material, the tissue is submerged in PBS during slicing to aid with slicing tissue Is submerged in ice and refrigerated for 30 minutes.
The required slice thickness in this case two millimeters is set and slices are cut At 20 RPM slices are cultured in a six well dish after two hours of Incubation at 37 degrees Celsius. Viral vectors are injected directly Into the slices. Slices are incubated for 24 hours in a 37 degrees incubator.
The next day, slices are analyzed for gene expression, but by a luminescent imaging.
View the full transcript and gain access to thousands of scientific videos
Overview
This article describes the culture of patient tissue slices for gene delivery studies and subsequent analysis of gene expression using IVIS bioluminescence imaging. The technique aims to improve the understanding of gene therapy in cancer treatment.
Key Study Components
Area of Science
- Gene therapy
- Cancer research
- Bioluminescence imaging
Background
- Gene therapy offers promising therapeutic approaches for cancer.
- Recent clinical trials have struggled to replicate animal model results.
- Understanding gene delivery in human tissues is crucial for advancing therapies.
- IVIS imaging provides a method for analyzing gene expression effectively.
Purpose of Study
- To culture patient tissue slices for gene delivery research.
- To analyze gene expression using advanced imaging techniques.
- To enhance the understanding of gene therapy outcomes in clinical settings.
Methods Used
- Culture of intact patient tissue slices.
- Gene delivery studies conducted on these slices.
- Analysis of gene expression through IVIS bioluminescence imaging.
- Comparison of results with previous animal model studies.
Main Results
- Successful culture of patient tissue slices for experimentation.
- Demonstrated gene delivery efficacy in human tissues.
- IVIS imaging provided clear insights into gene expression levels.
- Findings contribute to understanding discrepancies between human and animal studies.
Conclusions
- The study highlights the potential of using patient tissue for gene therapy research.
- IVIS bioluminescence imaging is effective for analyzing gene expression.
- Results may inform future clinical trials and therapeutic strategies.
Frequently Asked Questions
Executive Industry Relevance
This ex vivo patient tissue model addresses the critical gap between preclinical animal studies and clinical outcomes in gene therapy development. By enabling direct testing of gene delivery vectors in human tissue, the approach enhances predictive confidence and supports mechanistic de-risking prior to clinical trial entry. The system provides a disease-relevant platform for evaluating vector performance across normal and malignant tissues, informing portfolio decisions in oncology gene therapy programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in intact human tissue, clarifying gene delivery efficiency and expression patterns.
- Operational Value: Supports functional target validation by assessing vector performance in physiologically relevant patient-derived models.
- Predictive Value: Reduces mechanistic ambiguity by capturing inter-patient variability and tissue heterogeneity observed in clinical settings.
Screening & Assay Development
- Assay Readiness: Generates standardized, quantifiable bioluminescence readouts via IVIS imaging for comparing gene delivery conditions.
- Reproducibility: Maintains tissue viability and consistent slice thickness (2 mm) to support reproducible experimental outcomes across runs.
- Scalability: Compatible with multi-well plate formats, enabling parallel testing of viral and non-viral vectors under controlled conditions.
Translational & Preclinical Research
- Translational Continuity: Bridges discovery and preclinical stages by using actual patient tissue, improving relevance to human biology.
- Risk-Adjusted Decisions: Informs go/no-go criteria by identifying vector efficacy and limitations in human tissue before animal or clinical studies.
- Biomarker Alignment: Supports exploratory biomarker analysis through spatial and temporal gene expression mapping in intact tissue slices.
Pipeline & Workflow Integration
The method integrates into the discovery workflow as a human-relevant intermediate step between in vitro screening and in vivo models, particularly for oncology gene therapy candidates requiring validation in complex tissue environments.
- Discovery Biology: Facilitates hypothesis testing of gene delivery mechanisms in native tissue architecture, supporting pathway clarification and target engagement analysis.
- Screening: Enables assay development with quantitative, non-destructive readouts via bioluminescence, allowing longitudinal monitoring of expression without tissue sacrifice.
- Analytics: Provides measurable outputs (photon flux via IVIS) that allow statistical comparison of vector performance across tissue types and treatment conditions.
- Translational Research: Enhances preclinical validity by incorporating human tissue variability, reducing reliance on animal models that may not predict clinical response.
- Enterprise Reuse: Establishes a reusable platform for evaluating multiple gene therapy constructs across diverse tissue types, supporting cross-program standardization.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in gene therapy candidates by testing in human tissue, reducing false positives from animal models.
- Operational Value: Standardizes tissue preparation and imaging protocols, improving reproducibility and enabling multi-site collaboration.
- Strategic Value: Supports earlier identification of clinical translatability, optimizing resource allocation and reducing late-stage failure risk.
- Portfolio Impact: Enables data-driven prioritization of gene therapy candidates based on human tissue performance, improving risk-adjusted advancement.
Implementation Considerations
- Requires access to fresh patient tissue and expertise in surgical tissue handling and slicing techniques.
- Dependent on IVIS bioluminescence imaging infrastructure and luciferase-expressing vector systems for quantification.
- Necessitates standardized culture conditions to maintain tissue viability and consistent experimental outcomes.
- Must account for inter-patient variability in tissue response when interpreting results across donor samples.
- Limited by tissue availability and viability window, requiring coordinated logistics with surgical teams for timely processing.
